PDS Biotech to share new flu vaccine data at American Association of Immunologists’ IMMUNOLOGY2025 annual meeting

PDS Biotechnology Corporation, a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that preclinical immune response data with a novel Infectimune^® based flu vaccine will be featured in a symposium on universal influenza vaccines at the American Association of Immunologists’ IMMUNOLOGY2025™ Annual Meeting, taking place May 3-7, 2025, in Honolulu, Hawaii.

Details of the presentation are as follows:

Title: Broadly Protective Immunity against Influenza and Opportunities for Universal Influenza Vaccines
Session Type: Guest Symposium
Session Title: International Society of Influenza and Other Respiratory Viruses (ISIRIV) Symposium
Date, Time and Location: Sunday, May 4, 2025, 8:30–10:30 a.m. HST. Room 314
Presenter: Andrea Sant, Ph.D., Professor of Microbiology and Immunology at the University of Rochester Medical Center

Separately, PDS Biotech announced that, due to new U.S. National Institutes of Health policies regarding employee attendance at scientific conferences and meetings, the abstract “Alterations in peripheral T stem-like memory cells in patients with advanced solid tumors treated with tumor-targeting IL-12 therapy,” submitted by the National Cancer Institute, will no longer be part of Poster Sessions at the American Association for Cancer Research Annual Meeting 2025.